| Literature DB >> 35970887 |
Tomoya Fukuoka1,2, Kenta Moriwaki3, Shinji Takamatsu1, Jumpei Kondo1,4, Miki Tanaka-Okamoto5, Azusa Tomioka6, Manami Semba7,8, Sachiko Komazawa-Sakon7, Yoshihiro Kamada1,9, Hiroyuki Kaji6, Yasuhide Miyamoto5, Masahiro Inoue4, Kazuhiko Bessho2, Yoko Miyoshi2, Keiichi Ozono2, Hiroyasu Nakano7, Eiji Miyoshi10.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death and contributes to tumor rejection by cytotoxic lymphocytes in cancer immunosurveillance and immunotherapy. TRAIL and TRAIL receptor agonists have garnered wide popularity as promising agents for cancer therapy. We previously demonstrated that the loss of fucosylation in cancer cells impairs TRAIL sensitivity; however, the precise structures of the fucosylated glycans that regulate TRAIL sensitivity and their carrier molecules remain elusive. Herein, we observed that Lewis glycans among various fucosylated glycans positively regulate TRAIL-induced cell death. Specifically, Lewis glycans on lacto/neolacto glycosphingolipids, but not glycoproteins including TRAIL receptors, enhanced TRAIL-induced formation of the cytosolic caspase 8 complex, without affecting the formation of the membranous receptor complex. Furthermore, type I Lewis glycan expression in colon cancer cell lines and patient-derived cancer organoids was positively correlated with TRAIL sensitivity. These findings provide novel insights into the regulatory mechanism of TRAIL-induced cell death and facilitate the identification of novel predictive biomarkers for TRAIL-related cancer therapies in future.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35970887 DOI: 10.1038/s41388-022-02434-3
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 8.756